Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2999

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler, Denis Rybin, Andrew L. Frelinger, III, Alan D. Michelson, Ke Liu, Xiufeng Gao, Jennell White, Ahmar U. Zaidi, Robert J. Charnigo, Michael U. Callaghan

Blood (2021) 137 (15): 2010–2020.

https://doi.org/10.1182/blood.2020006020

Published: 2021

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Alexandra Kruse, Caroline Kruse, Nancy Potthast, Kelsey Milligan, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 2362.

https://doi.org/10.1182/blood-2019-122278

Published: 2019

Journal Articles

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Kristin A. Shimano, MD, Rachael F. Grace, MD, Carolyn M. Bennett, MDMSc, Robert J Klaassen, MD FRCPC, Cindy Neunert, MD, Ellis J. Neufeld, MD, Clement Ma, PhD, Wendy B. London, PhD, Jenny M. Despotovic, DO, MS

Blood (2019) 134 (Supplement_1): 2369.

https://doi.org/10.1182/blood-2019-125487

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD

Blood (2019) 134 (Supplement_1): 125.

https://doi.org/10.1182/blood-2019-129422

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Rachael F. Grace, MD, Paola Bianchi, BSc, PhD, Bertil Glader, MD PhD, Andreas Glenthøj, MD PhD, Bryan Jones, PhD, Hitoshi Kanno, MD PhD, Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB ChB, Eduard J. van Beers, MD PhD, Joan-Lluis Vives Corrons, MD PhD, Tu Xu, MS, PhD

Blood (2019) 134 (Supplement_1): 2223.

https://doi.org/10.1182/blood-2019-123059

Published: 2019

Journal Articles

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Blood (2019) 134 (Supplement_1): 5416.

https://doi.org/10.1182/blood-2019-129464

Published: 2019

Journal Articles

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Blood (2019) 134 (Supplement_1): 5296.

https://doi.org/10.1182/blood-2019-121997

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

Jill A. Bell, PhD MS, Farrah Anne Pompilus, MA, Alissa Rams, BA, Yanyan Zhu, PhD MPH, Anna Ciesluk, MPH, Rafael Bejar, MD PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Patrick Marquis, MD MBA

Blood (2019) 134 (Supplement_1): 5898.

https://doi.org/10.1182/blood-2019-128517

Published: 2019

Journal Articles

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Veronica A Guerra, MD, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Allison Pike, RN, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 5906.

https://doi.org/10.1182/blood-2019-127272

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

A complementary new drug for PNH

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only